Last reviewed · How we verify
felodipine/ramipril
felodipine/ramipril is a Calcium channel blocker/Angiotensin-converting enzyme inhibitor Small molecule drug developed by Abbott. It is currently in Phase 3 development for Hypertension, Heart failure.
Felodipine is a calcium channel blocker that relaxes blood vessels, while ramipril is an angiotensin-converting enzyme (ACE) inhibitor that lowers blood pressure.
Felodipine is a calcium channel blocker that relaxes blood vessels, while ramipril is an angiotensin-converting enzyme (ACE) inhibitor that lowers blood pressure. Used for Hypertension, Heart failure.
At a glance
| Generic name | felodipine/ramipril |
|---|---|
| Sponsor | Abbott |
| Drug class | Calcium channel blocker/Angiotensin-converting enzyme inhibitor |
| Target | Calcium channels/Angiotensin-converting enzyme |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Felodipine works by blocking the influx of calcium ions into smooth muscle cells, causing vasodilation and a decrease in blood pressure. Ramipril, on the other hand, inhibits the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby reducing blood pressure.
Approved indications
- Hypertension
- Heart failure
Common side effects
- Edema
- Dizziness
- Headache
- Nausea
- Cough
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- Efficacy and Safety of the Combination of Valsartan Plus Amlodipine in Hypertensive Patients Not Adequately Responding to the Combination Therapy With Ramipril Plus Felodipine (PHASE3)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
- China Medical University Hospital (CMUH) Triapin Listing (PHASE4)
- Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- felodipine/ramipril CI brief — competitive landscape report
- felodipine/ramipril updates RSS · CI watch RSS
- Abbott portfolio CI
Frequently asked questions about felodipine/ramipril
What is felodipine/ramipril?
How does felodipine/ramipril work?
What is felodipine/ramipril used for?
Who makes felodipine/ramipril?
What drug class is felodipine/ramipril in?
What development phase is felodipine/ramipril in?
What are the side effects of felodipine/ramipril?
What does felodipine/ramipril target?
Related
- Drug class: All Calcium channel blocker/Angiotensin-converting enzyme inhibitor drugs
- Target: All drugs targeting Calcium channels/Angiotensin-converting enzyme
- Manufacturer: Abbott — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Heart failure
- Compare: felodipine/ramipril vs similar drugs
- Pricing: felodipine/ramipril cost, discount & access